Entrar/Registro  
HOME SPANISH
 
Cirugía y Cirujanos
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Cirugía y Cirujanos >Year 2012, Issue 5


Arreola-Ornelas H, Rosado-Buzzo A, García-Mollinedo L, Dorantes-Aguilar J, Muciño-Ortega E, Mould-Quevedo JF
Economic analysis of dalteparin use in knee surgery at Instituto Mexicano del Seguro Social
Cir Cir 2012; 80 (5)

Language: Español
References: 27
Page: 411-418
PDF: 150.66 Kb.


Full text




ABSTRACT

Background: knee surgery is a risk factor for thromboembolic disease. Prophylaxis reduces the risk of this condition.
Methods: economic and health consequences of drugs preventing and treating thromboembolic disease in patients undergoing knee surgery from the institutional perspective (time horizon: one year) were estimated. The measures of effectiveness were: reduction in the number of cases (per 1,000 patients) of deep vein thrombosis, pulmonary embolism, hospital admissions and deaths. Transition probabilities were estimated by meta-analysis. The alternatives were: warfarin (reference), dalteparin, enoxaparin, nadroparin, unfractionated heparin + warfarin, and non-prophylaxis. Data on resources use and costs corresponds to the Instituto Mexicano del Seguro Social (IMSS). Acceptability curves were constructed.
Results: no prophylaxis implied three times higher cost ($18,835.1 versus $5,967.1) and less effectiveness in comparison with warfarin. The incremental cost-effectiveness ratios for enoxaparin were $3, $13, $17 y $3 per each additional case of deep vein thrombosis, pulmonary embolism, death and hospital admission avoided. Results of nadroparin and unfractionated heparin were inferior to warfarin (59.1% and 72.9% more costly and less effective in three measures of effectiveness, respectively). Dalteparin showed higher health outcomes and lower cost compared with warfarin (-20.6%). Dalteparin had a higher probability of being cost-effective than enoxaparin.
Discussion: thromboprophylaxis is a clinically and economically favorable alternative. The identification of a pharmacoeconomic profile of alternatives to perform it becomes relevant given the increasing pressure on institutional budgets.
Conclusions: dalteparin would be a cost-saving alternative in thromboprophylaxis of patients undergoing knee surgery at IMSS.


Key words: dalteparin, cost-effectiveness, venous thromboembolism, knee surgery.


REFERENCIAS

  1. Angulo Vázquez J, Ramírez García A, Torres Gómez LG, Vargas González A, Cortés Sanabria L. Tromboembolia pulmonar en obstetricia. Ginecol Obstet Méx 2004;72(8):400-406.

  2. Sigler L, Romero T, Meillón LA, Gutiérrez L, Aguirre García J, Esparza C. Tromboembolia pulmonar en autopsias en un período de 10 años. Rev Méd IMSS 1996;34(1):7-11.

  3. Ibarra-Pérez C, Lau-Cortés E, Colmenero-Zubiate S, Arévila-Ceballos N, Fong JH, Sánchez-Martínez R, et al. Prevalence and Prevention of Deep Venous Thrombosis of the Lower Extremities in High-Risk Pulmonary Patients. Angiology 1988;39(6):505-513.

  4. Sigler Morales L, Castañeda Gaxiola R, Vázquez V, Morales JJ. Mortalidad por enfermedad tromboembólica venosa en México durante 1997. Rev Mex Angiol 2002;30(4):125-128.

  5. Stringer MD, Steadman CA, Hedges AR, Thomas EM, Morley TR, Kakkar VV. Deep vein thrombosis after elective knee surgery. An incidence study in 312 patients. J Bone Joint Surg Br 1989;71-B(3):492-497.

  6. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):338S-400S.

  7. Angulo Vázquez J, Ramírez García A, Torres Gómez LG, Vargas González A, Cortés Sanabria L. Tromboembolia pulmonar en obstetricia. Ginecol Obstet Méx 2004;72(8):400-406.

  8. Sigler L, Romero T, Meillón LA, Gutiérrez L, Aguirre García J, Esparza C. Tromboembolia pulmonar en autopsias en un período de 10 años. Rev Méd IMSS 1996;34(1):7-11.

  9. Ibarra-Pérez C, Lau-Cortés E, Colmenero-Zubiate S, Arévila-Ceballos N, Fong JH, Sánchez-Martínez R, et al. Prevalence and Prevention of Deep Venous Thrombosis of the Lower Extremities in High-Risk Pulmonary Patients. Angiology 1988;39(6):505-513.

  10. Sigler Morales L, Castañeda Gaxiola R, Vázquez V, Morales JJ. Mortalidad por enfermedad tromboembólica venosa en México durante 1997. Rev Mex Angiol 2002;30(4):125-128.

  11. Stringer MD, Steadman CA, Hedges AR, Thomas EM, Morley TR, Kakkar VV. Deep vein thrombosis after elective knee surgery. An incidence study in 312 patients. J Bone Joint Surg Br 1989;71-B(3):492-497.

  12. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):338S-400S.

  13. Angulo Vázquez J, Ramírez García A, Torres Gómez LG, Vargas González A, Cortés Sanabria L. Tromboembolia pulmonar en obstetricia. Ginecol Obstet Méx 2004;72(8):400-406.

  14. Sigler L, Romero T, Meillón LA, Gutiérrez L, Aguirre García J, Esparza C. Tromboembolia pulmonar en autopsias en un período de 10 años. Rev Méd IMSS 1996;34(1):7-11.

  15. Ibarra-Pérez C, Lau-Cortés E, Colmenero-Zubiate S, Arévila-Ceballos N, Fong JH, Sánchez-Martínez R, et al. Prevalence and Prevention of Deep Venous Thrombosis of the Lower Extremities in High-Risk Pulmonary Patients. Angiology 1988;39(6):505-513.

  16. Sigler Morales L, Castañeda Gaxiola R, Vázquez V, Morales JJ. Mortalidad por enfermedad tromboembólica venosa en México durante 1997. Rev Mex Angiol 2002;30(4):125-128.

  17. Stringer MD, Steadman CA, Hedges AR, Thomas EM, Morley TR, Kakkar VV. Deep vein thrombosis after elective knee surgery. An incidence study in 312 patients. J Bone Joint Surg Br 1989;71-B(3):492-497.

  18. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):338S-400S.

  19. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Cohort Study. Arch Intern Med 2000;160:761-768.

  20. Consejo de Salubridad General. Comisión Interinstitucional del Cuadro Básico de Insumos del Sector Salud. Cuadro básico de medicamentos, Grupo 10: Hematología. Disponible en: http://www.csg.salud.gob.mx/descargas/pdfs/cuadro_basico/medicamentos/medicamentos_ed2010.pdf

  21. Pérez-García A, Briones-Pérez B. Tromboprofilaxis en pacientes postquirúrgicos: revisión de 1,500 casos. Cir Ciruj 2004;72(4):287-291.

  22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary? Control Clin Trials 1996;17(1):1-12.

  23. Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA Jr, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Exoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001;83-A(3):336-345.

  24. Fitzgerald RH, Spiro TE, Trowbridge AA, Gardiner GA Jr, Whitsett TL, O’Connell MB, et al. Prevention of Venous Thromboembolic Disease Following Primary Total Knee Arthroplasty: A Randomized, Multicenter, Open-Label, Parallel- Group Comparison of Enoxaparin and Warfarin. J Bone Joint Surg Am 2001;83-A(6):900-906.

  25. Eriksson BI, Bergqvisyt D, Kälebo P, Dahl OE, Lindbratt S, Bylock A, et al. Ximelagatran and Melagatran Compared with Dalteparin for Prevention of Venous Thromboembolism after Total Hip or Knee Replacement: The METHRO II Randomised Trial. Lancet 2002;360:1441-1447.

  26. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, l'Esperance B, Demers C, et al. Prevention of Venous Thromboembolism after Knee Arthroplasty. A Randomized, Double-Blind Trial Comparing Enoxaparin with Warfarin. Ann Intern Med 1996;124(7):619-626.

  27. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, et al. A comparison of Subcutaneous Low-Molecular-Weight Heparin with Warfarin Sodium for Prophylaxis against Deep-Vein Thrombosis after Hip or Knee Implantation. N Engl J Med 1993;329:1370-1376.

  28. Krotenberg R, Adler U, Pomeranz B, Miller JD, Russell MW. Dalteparin vs. enoxaparin as prophylaxis for deep-vein thrombosis after total hip or knee arthroplasty: a retrospective analysis. Am J Phys Med Rehabil 2001;80(12):889-895.

  29. Blanchard J, Meuwly JY, Leyvraz PF, Miron MJ, Bounameaux H, Hoffmeyer P, et al. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br 1999;81-B(4):654-659.

  30. Colwell CW, Spiro TE, Trowbridge AA, Stephens JWG, Gardiner GA Jr, Ritter MA. Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin for Prevention of Deep Venous Thrombosis After Elective Knee Arthroplasty. Clin Orthop Relat Res 1995;321:19-27.

  31. Faunø P, Suomalainen O, Rehnberg V, Hansen TB, Krøner K, Soimakallio S, et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin. J Bone Joint Surg Am 1994;76-A(12):1814-1818.

  32. Instituto Mexicano del Seguro Social. Base de datos de Estadísticas Médicas del Sistema Único de Información (SUI). Subsistema de Información 13 (SUI-13), Egresos hospitalarios. Sistema de Información Medico Operativa (SIMO), IMSS, México DF, 2006.

  33. Instituto Mexicano del Seguro Social. Base de datos de Estadísticas Médicas del Sistema Único de Información (SUI). Subsistema de Información

  34. 27 (SUI-27), Consulta Externa. Sistema de Información Medico Operativa (SIMO), IMSS, México DF, 2006.

  35. Instituto Mexicano del Seguro Social. Portal de Transparencia. Compra de bienes terapéuticos. Disponible en: http://transparencia.imss.gob.mx/cns_trnsp/ncompro.aspx?c=1

  36. Dirección de Finanzas del Instituto Mexicano del Seguro Social. Costos unitarios por el nivel de atención médica para el año 2011. Diario oficial de la Federación, 14 de Junio de 2011, Primera Sección, p. 79-82.

  37. Nerurkar J, Wade WE, Martin BC. Cost/Death Averted with Venous Thromboembolism Prophylaxis in Patients Undergoing Total Knee Replacement or Knee Arthroplasty. Pharmacotherapy 2002;22(8):990-1000.

  38. Hawkins DW, Langley PC, Krueger KP. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery. Clin Ther 1998;20(1):182-195.

  39. Dranitsaris G, Stumpo C, Smith R, Bartle W. Extended Dalteparin Prophylaxis for Venous Thromboembolic Events: Cost-Utility Analysis in Patients Undergoing Major Orthopedic Surgery. Am J Cardiovasc Drugs 2009;9(1):45-58.

  40. Lloyd A, Aitken JA, Hoffmeyer UK, Kelso EJ, Wakerly EC, Barber ND. Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy. Pharmacoeconomics 1997;12(4):475-485.






>Journals >Cirugía y Cirujanos >Year 2012, Issue 5
 

· Journal Index 
· Links 






       
Copyright 2019